Even with this dose and route optimization, however, the use of CRMP2-targeted therapies in neurological disorders is ultimately a newly developing field [6], and is even less developed in the context of Batten disease. Here, DPYSL2 is linked to juvenile neuronal ceroid lipofuscinosis.